ADMET Overview

Absorption, Distribution, Metabolism, Elimination & Toxicology (ADMET)

  • Roger S. Armen, PhD

    • Department of Pharmaceutical Sciences

    • Jefferson College of Pharmacy

    • PHRM 513: Medicinal Chemistry

    • Date: January 23, 2026

Lecture Objectives

  • Understand how functional groups determine the physiochemical properties of drugs and the fate of a drug molecule in the body.

  • Understand the following concepts:

    • Acid/base properties and their effect on drug solubility and absorption.

    • LogP and its effects on drug solubility and absorption.

    • How LogP and degree of ionization influence drug administration and appropriate dosage forms.

  • Explain the significance of ADMET properties as they relate to drug action and therapeutic effects.

Introduction to Drug Action

  • Drug Action:

    • Resulting from interactions of the drug with enzymes, receptors, or other molecules in the body.

  • Degree of Drug Activity is influenced by:

    • Concentration of the drug in an aqueous solution in contact with target proteins or receptors.

  • Factors affecting drug concentration are classified as:

    • Pharmacokinetic (PK) Phase:

    • Involves the movement of the drug from administration site to its action site (Absorption, Distribution, Metabolism, Elimination - ADME).

    • Pharmacodynamic (PD) Phase:

    • Relates to the chemical relationship between the drug and its target, which impacts pharmacological activity.

Pharmacokinetics

Plasma Concentration vs. Time

  • Graph: Plasma Concentration of BAY XX-XXXX after 5 mg/kg oral administration to rats.

    • Cmax concentration peaks at higher levels over time.

Oral Absorption & First Pass Metabolism

  • Passage Mechanisms:

    • Involves movement through membranes via:

    • Passive diffusion

    • Active transport

  • Orally administered drugs:

    • A significant fraction is absorbed into portal vein blood and directed towards the liver, where drug metabolism occurs.

    • First Pass Metabolism:

    • A process where a considerable amount of the administered dose is metabolized during its first encounter with the liver.

Distribution in the Body

  • Factors affecting drug distribution include:

    • Solubility (absorption)

    • Membrane permeability (A, D)

    • Efflux transporters (A, D)

    • Drug metabolism and clearance (M, E)

    • Drug-drug interactions (E)

    • Drug toxicity (T)

  • Key Sites:

    • Liver (drug metabolism)

    • Renal Clearance (E)

    • Tissue protein binding (D)

    • Cell permeability (D)

    • CNS (Central Nervous System) drug target

Physiochemical Properties Related to Absorption

  • Important factors include:

    • Degree of ionization at a specific pH (pKa)

    • Lipid/water solubility (LogP & LogD)

Log P and Lipid Partition Coefficient

  • Experimental Approach:

    • Measure the partitioning of a drug between octanol and water.

    • Why Octanol?:

    • Mimics lipid membrane environments due to its polar head and hydrocarbon chain.

    • Log P is defined as:
      extlogP=racextLogconcentrationofdruginoctanolextconcentrationofdruginwaterext{log P} = rac{ ext{Log concentration of drug in octanol}}{ ext{concentration of drug in water}}

    • Example: At equilibrium, ratios of molecules in lipid versus aqueous phases are described.

Practical Implications for Log P Values

  • Rules of thumb for Log P:

    • Optimal CNS penetration: Log P ≈ 2 ± 0.7

    • Optimal Oral absorption: Log P ≈ 1.8

    • Optimal Intestinal absorption: Log P ≈ 1.35

    • Optimal Colonic absorption: Log P ≈ 1.32

    • Optimal Sublingual absorption: Log P ≈ 5.5

    • Optimal Percutaneous absorption: Log P ≈ 2.6

  • Approximate ranges for Log P:

    • Low Log P (<0): Injectable medications

    • Medium Log P (0-3): Oral formulations

    • High Log P (3-4): Transdermal medications

    • Very High (4-7): Risks of toxic accumulation in fatty tissues.

Predicting LogP Based on Functional Groups

  • Empirical Approach Developed by Lemke:

    • Carbon-solubilizing potential (CSP) of organic functional groups (FGs) determines solubility.

  • A molecule is considered water soluble if the CSP of FGs exceeds the total number of carbon atoms in the molecule.

    • Example with glucose:

    • Contains 6 FGs including ethers and alcohols, leading to high CSP (17).

    • Thus, glucose is predicted to be very water soluble.

Carbon Solubilizing Potential of Organic Functional Groups

  • Water solubilizing potentials vary by functional group type in mono- or polyfunctional molecules:

    • Monofunctional Molecule Water Solubility:

    • Alcohol, Phenol: 5 to 6 carbons.

    • Ether, Ketone, Amine, Carboxylic Acid: 4 to 5 to 6 carbons.

    • Polyfunctional Molecule Water Solubility:

    • Alcohol, Amine, etc.: Typically require fewer carbons due to multiple FGs enhancing solubility.

Prediction of Water Solubility Example

  • Example with Anileridine (a narcotic analgesic):

    • Contains 3 functional groups:

    • Aromatic amine, tertiary alkyl amine, and ester (Total CSP = 9).

    • Total carbon atoms = 21 (CSP < N carbon atoms) indicates low water solubility (0.01% solubility reported in U.S. Pharmacopeia (USP)).

Physiochemical Properties and Absorption Factors

  • Factors include:

    • Degree of ionization (pKa)

    • Lipid/water solubility (LogP/LogD)

    • Molecular size (Molecular Weight)

    • Dosage formulation and concentration.

    • Dissolution requirement: transition from solid to aqueous state is key for absorption.

Membrane Permeability

  • Passive membrane diffusion involves:

    • Greater degree of ionization at specific pH increases absorption rates for neutral compounds compared to charged ones.

    • Increased LogP enhances membrane permeability.

    • Molecular weight significantly impacts permeability; lower MW means generally better permeability.

  • Dosage Formulation:

    • Dosage design may affect absorption through alterations in solid-state properties (e.g., particle size, excipients).

General Rules of Oral Absorption

  • Absorption primarily occurs in the small intestine due to:

    • Larger surface area and longer contact time compared to the stomach.

    • Greater permeability of intestinal membranes than gastric mucosal layers.

  • Gastric Emptying:

    • Often rate-limiting factor for absorption, influenced by food intake (e.g., fatty foods slow gastric emptying).

    • Stomach pH varies (1.4 to 8 across sections).

Drug Absorption Mechanisms

  • Passage from administration site into plasma occurs via:

    • Routes including injection, oral, rectal, sublingual.

  • Mechanisms include:

    • Passive diffusion, active transport, endocytosis, exocytosis.

Non-Oral Routes of Administration

  • Topical/Transdermal:

    • Few drugs can penetrate skin effectively.

  • Sublingual:

    • Avoids first-pass metabolism through venous drainage into the superior vena cava.

  • Rectal:

    • ~50% of the drug bypasses the liver, reducing first-pass metabolism.

  • Pulmonary:

    • Instantaneous absorption, avoids first-pass metabolism.

  • Parenteral:

    • Includes injection types: subcutaneous, intramuscular, intraperitoneal, intravenous.

Desirable Drug Properties

  • Essential properties include:

    • Adequate solubility & absorption (A)

    • Sufficient concentration in target tissues (D)

    • Appropriate metabolic stability & low toxic metabolite formation (T)

    • Extensive interaction with intended targets (D)

    • Minimal interaction with unintended targets (T)

    • Minimized interaction with co-administered drugs (M, T)

    • Minimal toxicity (T) and appropriate elimination rates (E)

  • ADMET properties are crucial for clinical success and optimal drug candidate selection.

Lipinski’s “Rule of Five”

  • Guidelines for drug-like small molecules:

    • Molecular Weight (MW) < 500 daltons

    • Calculated LogP < 5

  • Minor rules include:

    • ≤ 5 hydrogen bond donors (e.g., N-H or O-H)

    • ≤ 10 hydrogen bond acceptors (e.g., carbonyl groups, O, N, S).

  • Exceptions exist for drugs acting as biological transporter substrates.

  • Oral absorption: Requires a balance between drug solubility and membrane permeability.

Drug Distribution

  • Transportation from administration site to action site primarily occurs through:

    • Blood circulation (major)

    • Lymphatic system (minor)

  • Drugs are distributed quickly to all body areas accessible by blood.

  • Implications:

    • Chemical and physical properties of blood influence drug concentration at action sites.

Drug Transport & Plasma Proteins

  • Drugs may exist in blood as free entities or bound to plasma proteins (mostly reversible).

  • Equilibrium:

    • Bound drugs have no pharmacological effect until released.

  • Displacement Implications:

    • One drug may displace another if it binds more stably to plasma proteins, affecting drug efficacy and interactions.

Major Plasma Proteins in Drug Binding

  • Serum Albumin:

    • Binds to acidic and neutral drugs, predominant serum protein.

  • Alpha-1 Acid Glycoprotein:

    • Binds to basic drugs.

  • Other Proteins:

    • Lipoproteins and a, b, g-globulins also play a role.

Role of Drug Transporters

  • Transporters facilitate drug passage from the gut to circulation and regulate drug movement in/out of the liver and kidneys.

  • Key transport mechanisms:

    • Passive diffusion and active transport via transporters, endocytosis, and exocytosis.

Different Drug Transporters

  • In the Gastrointestinal Tract:

    • P-glycoprotein (P-gp): Transports several CYP3A4 substrates.

    • Multidrug resistance proteins (MRP2, MRP4): Highly expressed in the small intestine.

    • Peptide transporter 1 (PEPT1): Transports di- and tri-peptides and drugs mimicking amino acids.

    • Organic ion transporters (OATP, OAT, OCT): Responsible for various drug movements.

Drug Metabolism

  • Refers to the biological transformation of drug molecules into metabolites for excretion (usually via urine).

  • Functions of Drug Metabolism:

    • Typically detoxifies and increases water solubility of drugs.

    • Can also lead to increased toxicity, activation, or deactivation of biological activity.

    • Primary site of metabolism: liver, but can also occur in other locations (e.g., kidneys, lungs, etc.).

  • Xenobiotics:

    • Any foreign substance to the body can undergo metabolism, making this a key consideration in drug development.

Drug Metabolism & Elimination

Relationship between Liver & Kidney

  • Primary excretion routes include:

    • Kidneys (via glomerular filtration or tubular secretion).

    • Other excretion forms: feces and minimal other forms (sweating, exhalation).

  • Example:

    • Thalidomide use during pregnancy led to drug-induced malformations in neonates (teratogenesis).

Drug Elimination

  • Involves removal of active drug forms from the body:

    • Via metabolism and all forms of excretion.

    • Reduces concentrations at action sites, affecting therapeutic effects.

  • Slow Elimination Advantages:

    • May reduce required dosing and decrease side effects.

  • Risks of Slow Elimination:

    • Potential drug deposition in tissues and increased toxicity risks.

  • Rapid Elimination:

    • May require increased dosing and raise risks of side effects.

  • Rate of Elimination:

    • A critical factor in drug design and development.